Literature DB >> 731408

Rate of phenytoin accumulation in man: a simulation study.

T M Ludden, J P Allen, L W Schneider, S A Stavchansky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 731408     DOI: 10.1007/bf01062722

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


× No keyword cloud information.
  24 in total

1.  Bioavailability of phenytoin. A comparison of two preparations.

Authors:  M J Stewart; B R Ballinger; E J Devlin; A Y Miller; A C Ramsay
Journal:  Eur J Clin Pharmacol       Date:  1975-12-19       Impact factor: 2.953

2.  A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments.

Authors:  A Richens
Journal:  Epilepsia       Date:  1975-11       Impact factor: 5.864

3.  Nonlinear assessment of phenytoin bioavailability.

Authors:  W J Jusko; J R Koup; G Alván
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

4.  Pharmacokinetic study of a patient with diphenylhydantoin toxicity.

Authors:  A J Atkinson; J M Shaw
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

6.  Bioavailability of 11 phenytoin products.

Authors:  A P Melikian; A B Straughn; G W Slywka; P L Whyatt; M C Meyer
Journal:  J Pharmacokinet Biopharm       Date:  1977-04

7.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

8.  Diphenylhydantoin elimination kinetics in overdosed children.

Authors:  L K Garrettson; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

9.  The elimination of phenytoin in man.

Authors:  M J Eadie; J H Tyrer; F Bochner; W D Hooper
Journal:  Clin Exp Pharmacol Physiol       Date:  1976 May-Jun       Impact factor: 2.557

10.  Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Plasma levels and urinary metabolites; and studies in healthy volunteers.

Authors:  N Gerber; R Lynn; J Oates
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

View more
  5 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

3.  Rapid and slow release phenytoin in epileptic patients at steady state: comparative plasma levels and toxicity.

Authors:  R J Sawchuk; S M Pepin; I E Leppik; R J Gumnit
Journal:  J Pharmacokinet Biopharm       Date:  1982-08

4.  Nomographic estimation of time to reach steady-state serum concentration during phenytoin therapy.

Authors:  S Vozeh; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

5.  Steady-state plasma concentrations as a function of the absorption rate and dosing interval for drugs exhibiting concentration-dependent clearance: consequences for phenytoin therapy.

Authors:  R J Sawchuk; T S Rector
Journal:  J Pharmacokinet Biopharm       Date:  1979-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.